688098 申联生物
已收盘 06-25 15:00:01
资讯
新帖
简况
股市必读：申联生物（688098）6月15日董秘有最新回复
证券之星 · 06-16
股市必读：申联生物（688098）6月15日董秘有最新回复
申联生物：2025年年度业绩说明会采用上证路演中心网络互动的方式
证券之星 · 06-15
申联生物：2025年年度业绩说明会采用上证路演中心网络互动的方式
6月10日申联生物涨6.18%，中信建投趋势领航两年持有混合A基金重仓该股
证券之星 · 06-10
6月10日申联生物涨6.18%，中信建投趋势领航两年持有混合A基金重仓该股
申联生物：UB-211已于2026年5月完成II期临床试验全部受试者出组
证券之星 · 06-08
申联生物：UB-211已于2026年5月完成II期临床试验全部受试者出组
申联生物：公司生产经营活动一切正常
证券之星 · 06-03
申联生物：公司生产经营活动一切正常
每周股票复盘：申联生物（688098）设立2026年员工持股计划
证券之星 · 05-31
每周股票复盘：申联生物（688098）设立2026年员工持股计划
申联生物（688098）披露2026年员工持股计划第一次持有人会议决议公告，5月27日股价下跌0.99%
证券之星 · 05-27
申联生物（688098）披露2026年员工持股计划第一次持有人会议决议公告，5月27日股价下跌0.99%
每周股票复盘：申联生物（688098）推2026员工持股计划
证券之星 · 05-24
每周股票复盘：申联生物（688098）推2026员工持股计划
申联生物（688098）披露2025年年度股东会决议公告，5月20日股价下跌1.88%
证券之星 · 05-20
申联生物（688098）披露2025年年度股东会决议公告，5月20日股价下跌1.88%
申联生物最新公告：获批仔猪副伤寒活疫苗产品批准文号
证券之星 · 05-08
申联生物最新公告：获批仔猪副伤寒活疫苗产品批准文号
每周股票复盘：申联生物（688098）Q1净利同比升42.68%
证券之星 · 05-02
每周股票复盘：申联生物（688098）Q1净利同比升42.68%
申联生物(688098)3月31日股东户数1.01万户，较上期减少7.88%
证券之星 · 04-29
申联生物(688098)3月31日股东户数1.01万户，较上期减少7.88%
图解申联生物年报：第四季度单季净利润同比增长32.15%
证券之星 · 04-29
图解申联生物年报：第四季度单季净利润同比增长32.15%
动物保健概念震荡反弹，申联生物涨停
每日经济新闻 · 04-07
动物保健概念震荡反弹，申联生物涨停
每周股票复盘：申联生物（688098）拟收购联营公司控股权
证券之星 · 03-15
每周股票复盘：申联生物（688098）拟收购联营公司控股权
申联生物（688098）披露2026年第一次临时股东会决议公告，3月12日股价下跌0.55%
证券之星 · 03-12
申联生物（688098）披露2026年第一次临时股东会决议公告，3月12日股价下跌0.55%
股市必读：申联生物发布2025年度业绩快报，亏损0.191亿元
证券之星 · 03-02
股市必读：申联生物发布2025年度业绩快报，亏损0.191亿元
每周股票复盘：申联生物（688098）2025年净亏1909万同比减亏57.33%
证券之星 · 03-01
每周股票复盘：申联生物（688098）2025年净亏1909万同比减亏57.33%
申联生物控股世之源转型发展“人药”，目标公司尚未盈利
新京报 · 02-25
申联生物控股世之源转型发展“人药”，目标公司尚未盈利
动保业务颓势难改，申联生物跨界掘金人用创新药，续亏之下双主业谋变待考
中金财经 · 02-25
动保业务颓势难改，申联生物跨界掘金人用创新药，续亏之下双主业谋变待考
加载更多
公司概况
公司名称：
申联生物医药(上海)股份有限公司
所属行业：
医药制造业
上市日期：
2019-10-28
主营业务：
申联生物医药(上海)股份有限公司的主营业务是动物预防、治疗及诊断生物产品的研发、生产和销售。公司的主要产品是系列猪、牛羊口蹄疫疫苗、猪圆环病毒2型亚单位疫苗、猪瘟E2亚单位疫苗。
发行价格：
8.80
{"stockData":{"symbol":"688098","market":"SH","secType":"STK","nameCN":"申联生物","latestPrice":9.02,"timestamp":1782370801000,"preClose":9.16,"halted":0,"volume":4800721,"delay":0,"changeRate":-0.0153,"floatShares":411000000,"shares":411000000,"eps":-0.0468,"marketStatus":"已收盘","change":-0.14,"latestTime":"06-25 15:00:01","open":9.18,"high":9.27,"low":8.89,"amount":43478200,"amplitude":0.0415,"askPrice":9.05,"askSize":754,"bidPrice":9.02,"bidSize":52,"shortable":0,"etf":0,"ttmEps":-0.0468,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1782437400000},"marketStatusCode":5,"adr":0,"adjPreClose":9.16,"symbolType":"stock_kcb","openAndCloseTimeList":[[1782351000000,1782358200000],[1782363600000,1782370800000]],"highLimit":10.08,"lowLimit":8.24,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":410644000,"isCdr":false,"pbRate":2.67,"roa":"--","roe":"--","epsLYR":-0.05,"committee":-0.663278,"marketValue":3704000000,"turnoverRate":0.0117,"status":1,"afterMarket":{"amount":0,"volume":0,"close":9.02,"buyVolume":683,"sellVolume":0,"time":1782372837746,"indexStatus":"已收盘 06-25 15:30:00","preClose":9.16},"floatMarketCap":3704000000},"requestUrl":"/m/hq/s/688098","defaultTab":"news","newsList":[{"id":"2643478318","title":"股市必读：申联生物（688098）6月15日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2643478318","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643478318?lang=zh_cn&edition=full","pubTime":"2026-06-16 03:24","pubTimestamp":1781551487,"startTime":"0","endTime":"0","summary":"截至2026年6月15日收盘，申联生物报收于8.53元，上涨2.28%，换手率0.89%，成交量3.67万手，成交额3121.87万元。董秘最新回复投资者： 最近美国拟对医药提出的两个法案《FDA法案》和巜COINS法案》对贵公司有无影响？公司将持续关注相关法案的进展，并积极研究其对行业的潜在影响。当日关注点交易信息汇总：6月15日主力资金净流入104.57万元，游资资金净流入19.4万元，散户资金净流出123.97万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061600004387.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688098","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643276114","title":"申联生物：2025年年度业绩说明会采用上证路演中心网络互动的方式","url":"https://stock-news.laohu8.com/highlight/detail?id=2643276114","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643276114?lang=zh_cn&edition=full","pubTime":"2026-06-15 16:33","pubTimestamp":1781512421,"startTime":"0","endTime":"0","summary":"证券之星消息，申联生物06月15日在投资者关系平台上答复投资者关心的问题。基于此，请问贵公司在2025年年度业绩说明会中，是否考虑采用视频直播并提供会后回放，以提升信息获取的便利性与透明度？公司2025年年度业绩说明会采用上证路演中心网络互动的方式，您可以通过上证路演中心官网查看本次说明会的召开情况及主要内容。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061500019868.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688098"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642499724","title":"6月10日申联生物涨6.18%，中信建投趋势领航两年持有混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2642499724","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642499724?lang=zh_cn&edition=full","pubTime":"2026-06-10 16:38","pubTimestamp":1781080693,"startTime":"0","endTime":"0","summary":"证券之星消息，6月10日申联生物涨6.18%，收盘报8.08元，换手率1.48%，成交量6.07万手，成交额4862.71万元。重仓申联生物的公募基金请见下表：根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为中信建投基金的中信建投趋势领航两年持有混合A。中信建投趋势领航两年持有混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061000029286.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688098","601066","BK0276","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641483194","title":"申联生物：UB-211已于2026年5月完成II期临床试验全部受试者出组","url":"https://stock-news.laohu8.com/highlight/detail?id=2641483194","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641483194?lang=zh_cn&edition=full","pubTime":"2026-06-08 18:06","pubTimestamp":1780913173,"startTime":"0","endTime":"0","summary":"证券之星消息，申联生物06月08日在投资者关系平台上答复投资者关心的问题。做点实事吧，不要只想着讲故事申联生物回复：投资者您好，感谢您对公司的关注与建议。关于股份回购事宜，公司已于2024年12月至2025年5月23日期间，累计回购股份3,417,373股，回购总金额达2,000万元。其中，UB-211已于2026年5月完成II期临床试验全部受试者出组。后续取得临床研究总结报告等关键进展时，公司将严格履行信息披露义务，敬请关注公司相关公告。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060800025122.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688098"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640908299","title":"申联生物：公司生产经营活动一切正常","url":"https://stock-news.laohu8.com/highlight/detail?id=2640908299","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640908299?lang=zh_cn&edition=full","pubTime":"2026-06-03 17:48","pubTimestamp":1780480102,"startTime":"0","endTime":"0","summary":"证券之星消息，申联生物06月03日在投资者关系平台上答复投资者关心的问题。公司生产经营活动一切正常，内部经营秩序良好，不存在应披露而未披露的重大信息。此外，股票价格受到宏观经济、二级市场波动等诸多因素影响，敬请投资者注意投资风险。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060300036632.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688098","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639604250","title":"每周股票复盘：申联生物（688098）设立2026年员工持股计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2639604250","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639604250?lang=zh_cn&edition=full","pubTime":"2026-05-31 04:01","pubTimestamp":1780171297,"startTime":"0","endTime":"0","summary":"截至2026年5月29日收盘，申联生物报收于7.78元，较上周的8.23元下跌5.47%。本周，申联生物5月25日盘中最高价报8.41元。申联生物当前最新总市值31.95亿元，在动物保健板块市值排名10/10，在两市A股市值排名4358/5207。本周关注点公司公告汇总：申联生物设立2026年员工持股计划，选举产生管理委员会成员。所有议案均获全票通过。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026053100001205.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688098","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638460689","title":"申联生物（688098）披露2026年员工持股计划第一次持有人会议决议公告，5月27日股价下跌0.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638460689","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638460689?lang=zh_cn&edition=full","pubTime":"2026-05-27 22:43","pubTimestamp":1779892994,"startTime":"0","endTime":"0","summary":"截至2026年5月27日收盘，申联生物报收于7.98元，较前一交易日下跌0.99%，最新总市值为32.77亿元。该股当日开盘8.07元，最高8.12元，最低7.91元，成交额达1627.36万元，换手率为0.5%。近日，申联生物披露《2026年员工持股计划第一次持有人会议决议公告》。公告显示，公司召开2026年员工持股计划第一次持有人会议，审议通过设立员工持股计划管理委员会，并选举于海霞、王蕾、王锐为委员，其中王锐任主任。所有议案均获全票通过。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052700046376.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688098"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637337615","title":"每周股票复盘：申联生物（688098）推2026员工持股计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2637337615","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637337615?lang=zh_cn&edition=full","pubTime":"2026-05-24 05:02","pubTimestamp":1779570136,"startTime":"0","endTime":"0","summary":"截至2026年5月22日收盘，申联生物报收于8.23元，较上周的8.49元下跌3.06%。本周关注点公司公告汇总：申联生物发布2026年员工持股计划，拟参与人数不超过65人。公司公告汇总：2026年员工持股计划考核目标为取得4项兽 药批准文号并实现4款新疫苗上市。申联生物发布2026年员工持股计划，拟参与人数不超过65人，资金来源为员工合法薪酬及自筹资金，股份来源为公司回购专用账户中不超过341.7373万股股份，约占总股本0.83%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052400001604.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688098"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636251918","title":"申联生物（688098）披露2025年年度股东会决议公告，5月20日股价下跌1.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636251918","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636251918?lang=zh_cn&edition=full","pubTime":"2026-05-20 22:39","pubTimestamp":1779287953,"startTime":"0","endTime":"0","summary":"截至2026年5月20日收盘，申联生物报收于8.37元，较前一交易日下跌1.88%，最新总市值为34.37亿元。该股当日开盘8.47元，最高8.56元，最低8.28元，成交额达1924.95万元，换手率为0.56%。近日，申联生物医药(上海)股份有限公司披露《2025年年度股东会决议公告》。中小投资者对部分议案单独计票，相关关联股东已回避表决。上海市锦天城律师事务所对本次会议出具法律意见书，认为会议决议合法有效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052000043508.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688098","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633434126","title":"申联生物最新公告：获批仔猪副伤寒活疫苗产品批准文号","url":"https://stock-news.laohu8.com/highlight/detail?id=2633434126","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633434126?lang=zh_cn&edition=full","pubTime":"2026-05-08 17:59","pubTimestamp":1778234369,"startTime":"0","endTime":"0","summary":"申联生物(688098.SH)公告称，公司兰州分公司获批仔猪副伤寒活疫苗(商品名：联痢清)兽药产品批准文号，该产品用于预防仔猪副伤寒，在“减抗禁抗”背景下具有市场空间。产品上市前需履行批签发程序，无需其他审批。此次获批将完善公司细菌疫苗产品矩阵，提升综合服务能力，但销售受多重因素影响，收益存在不确定性。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050800032509.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688098"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632623384","title":"每周股票复盘：申联生物（688098）Q1净利同比升42.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2632623384","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632623384?lang=zh_cn&edition=full","pubTime":"2026-05-02 05:52","pubTimestamp":1777672336,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，申联生物报收于8.84元，较上周的8.67元上涨1.96%。本周，申联生物4月30日盘中最高价报8.99元。本周关注点来自业绩披露要点：申联生物2026年一季报显示归母净利润-173.1万元，同比上升42.68%。股本股东变化截至2026年3月31日，申联生物股东户数为1.01万户，较2025年12月31日减少861户，减幅7.88%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050200003139.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688098"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631596321","title":"申联生物(688098)3月31日股东户数1.01万户，较上期减少7.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631596321","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631596321?lang=zh_cn&edition=full","pubTime":"2026-04-29 17:42","pubTimestamp":1777455725,"startTime":"0","endTime":"0","summary":"证券之星消息，近日申联生物披露，截至2026年3月31日公司股东户数为1.01万户，较12月31日减少861.0户，减幅为7.88%。在动物保健行业个股中，申联生物股东户数低于行业平均水平，截至3月31日，动物保健行业平均股东户数为2.23万户。从股价来看，2025年12月31日至2026年3月31日，申联生物区间跌幅为2.82%，在此期间股东户数减少861.0户，减幅为7.88%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900055311.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688098","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631874425","title":"图解申联生物年报：第四季度单季净利润同比增长32.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631874425","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631874425?lang=zh_cn&edition=full","pubTime":"2026-04-29 02:21","pubTimestamp":1777400519,"startTime":"0","endTime":"0","summary":"证券之星消息，申联生物2025年年报显示，当年度公司主营收入2.88亿元，同比下降4.99%；归母净利润-2049.5万元，同比上升54.19%；扣非净利润-2598.46万元，同比上升46.29%；其中2025年第四季度，公司单季度主营收入5057.17万元，同比下降8.24%；单季度归母净利润-2077.31万元，同比上升32.15%；单季度扣非净利润-2088.39万元，同比上升36.4%；负债率9.3%，投资收益-300.45万元，财务费用-3.36万元，毛利率56.82%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900006463.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688098"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625986724","title":"动物保健概念震荡反弹，申联生物涨停","url":"https://stock-news.laohu8.com/highlight/detail?id=2625986724","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625986724?lang=zh_cn&edition=full","pubTime":"2026-04-07 10:13","pubTimestamp":1775527980,"startTime":"0","endTime":"0","summary":"每经AI快讯，4月7日，动物保健概念震荡反弹，申联生物涨停，中牧股份、亨通股份、大洋生物、利民股份、蔚蓝生物、圣达生物等跟涨。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-04-07/doc-inhtrumh0456925.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-04-07/doc-inhtrumh0456925.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688098","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619217860","title":"每周股票复盘：申联生物（688098）拟收购联营公司控股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2619217860","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619217860?lang=zh_cn&edition=full","pubTime":"2026-03-15 02:56","pubTimestamp":1773514570,"startTime":"0","endTime":"0","summary":"截至2026年3月13日收盘，申联生物报收于9.01元，较上周的9.2元下跌2.07%。本周，申联生物3月13日盘中最高价报9.32元。本周关注点公司公告汇总：申联生物拟收购联营公司控股权并开展新业务。公司公告汇总申联生物医药（上海）股份有限公司于2026年3月12日召开2026年第一次临时股东会，审议通过《关于续聘会计师事务所的议案》和《关于收购联营公司控股权并开展新业务暨关联交易的议案》。第二项议案对中小投资者单独计票，关联股东已回避表决。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031500000854.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688098","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618426130","title":"申联生物（688098）披露2026年第一次临时股东会决议公告，3月12日股价下跌0.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618426130","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618426130?lang=zh_cn&edition=full","pubTime":"2026-03-12 22:48","pubTimestamp":1773326896,"startTime":"0","endTime":"0","summary":"截至2026年3月12日收盘，申联生物报收于9.01元，较前一交易日下跌0.55%，最新总市值为37亿元。该股当日开盘9.1元，最高9.1元，最低9.0元，成交额达1570.01万元，换手率为0.42%。申联生物医药（上海）股份有限公司于2026年3月12日召开2026年第一次临时股东会，审议通过《关于续聘会计师事务所的议案》和《关于收购联营公司控股权并开展新业务暨关联交易的议案》。第二项议案对中小投资者单独计票，关联股东已回避表决。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031200039151.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688098"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616987629","title":"股市必读：申联生物发布2025年度业绩快报，亏损0.191亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2616987629","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616987629?lang=zh_cn&edition=full","pubTime":"2026-03-02 03:18","pubTimestamp":1772392693,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，申联生物报收于9.7元，上涨1.68%，换手率0.83%，成交量3.4万手，成交额3281.78万元。业绩披露要点业绩快报申联生物近日即将发布2025年年报，根据2月27日发布的业绩快报，归属净利润亏损0.191亿元，同比增长57.33%。公司公告汇总2025年度业绩快报公告申联生物发布2025年度业绩快报，营业总收入28,826.65万元，同比下降4.99%；归属于母公司所有者的净利润为-1,909.07万元，较上年减亏57.33%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030200001496.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688098","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616459938","title":"每周股票复盘：申联生物（688098）2025年净亏1909万同比减亏57.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616459938","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616459938?lang=zh_cn&edition=full","pubTime":"2026-03-01 02:50","pubTimestamp":1772304618,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，申联生物报收于9.7元，较上周的9.66元上涨0.41%。本周，申联生物2月25日盘中最高价报10.34元。本周关注点业绩披露要点：申联生物2025年净亏1909.07万元，同比减亏57.33%。业绩披露要点申联生物近日即将发布2025年年报，根据2月27日发布的业绩快报，归属净利润亏损0.191亿元，同比增长57.33%。营业总收入28,826.65万元，同比下降4.99%；归属于母公司所有者的净利润为-1,909.07万元，较上年减亏57.33%。一致行动人上海申源启航出资7,995.6392万元取得世之源10.35%股权。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100001031.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688098","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614805460","title":"申联生物控股世之源转型发展“人药”，目标公司尚未盈利","url":"https://stock-news.laohu8.com/highlight/detail?id=2614805460","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614805460?lang=zh_cn&edition=full","pubTime":"2026-02-25 21:28","pubTimestamp":1772026080,"startTime":"0","endTime":"0","summary":"本次交易完成后，申联生物能够控制世之源51%股权的表决权，世之源成为申联生物的控股孙公司，纳入合并报表范围。申联生物表示，公司通过收购世之源控股权，整合其在创新药领域的核心研发能力与技术平台体系，强化人用药板块的研发管线与产业化基础。2021年以来，申联生物归母净利润持续下滑，2024年陷入亏损。2025年业绩预告显示，申联生物预计实现归属于母公司所有者的净利润约-2000万元。","market":"us","thumbnail":"https://media.bjnews.com.cn/fz/html/AttachPubDev/2026/2/wangl8820262251659242922617.jpg?x-oss-process=image/resize,m_lfit,w_365/quality,q_80","type":0,"news_type":0,"thumbnails":["https://media.bjnews.com.cn/fz/html/AttachPubDev/2026/2/wangl8820262251659242922617.jpg?x-oss-process=image/resize,m_lfit,w_365/quality,q_80"],"rights":{"source":"highlight_bjnews","url":"https://www.bjnews.com.cn/detail/1772026117168567.html","rn_cache_url":null,"customStyle":"handleCustomStyle(customStyle, ThemeStyle, getFont(fontSize))","selectors":"#main .nleft","filters":".ntit, .attitude","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bjnews.com.cn/detail/1772026117168567.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_bjnews","symbols":["688098","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614092437","title":"动保业务颓势难改，申联生物跨界掘金人用创新药，续亏之下双主业谋变待考","url":"https://stock-news.laohu8.com/highlight/detail?id=2614092437","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614092437?lang=zh_cn&edition=full","pubTime":"2026-02-25 16:23","pubTimestamp":1772007786,"startTime":"0","endTime":"0","summary":"标的世之源手握三款分别针对病毒感染和过敏免疫领域的在研创新药，申联生物试图通过收购切入人用创新药赛道，剑指“人用药品+ 动物保健”双主业发展格局。收购完成后，申联生物将形成“人用药品”与“动物保健”双主业协同发展的新格局。收购世之源，申联生物寄予一定厚望，但也面临重重挑战。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260225/32026374.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["159992","BK1574","688098","BK0239","06978","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1782377199820,"stockEarnings":[{"period":"1week","weight":0.0651},{"period":"1month","weight":0.1023},{"period":"3month","weight":0.1076},{"period":"6month","weight":0.0281},{"period":"1year","weight":0.5318},{"period":"ytd","weight":0.0315}],"compareEarnings":[{"period":"1week","weight":0.0007},{"period":"1month","weight":-0.0101},{"period":"3month","weight":0.057},{"period":"6month","weight":0.0371},{"period":"1year","weight":0.2018},{"period":"ytd","weight":0.0358}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"申联生物医药(上海)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"10068人(较上一季度减少7.88%)","perCapita":"40787股","listingDate":"2019-10-28","address":"上海市闵行区江川东路48号","registeredCapital":"41064万元","survey":" 申联生物医药(上海)股份有限公司的主营业务是动物预防、治疗及诊断生物产品的研发、生产和销售。公司的主要产品是系列猪、牛羊口蹄疫疫苗、猪圆环病毒2型亚单位疫苗、猪瘟E2亚单位疫苗。","listedPrice":8.8},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"申联生物(688098)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供申联生物(688098)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"申联生物,688098,申联生物股票,申联生物股票老虎,申联生物股票老虎国际,申联生物行情,申联生物股票行情,申联生物股价,申联生物股市,申联生物股票价格,申联生物股票交易,申联生物股票购买,申联生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"申联生物(688098)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供申联生物(688098)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}